Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK based Sareum Holdings has reported an additional in-house drug discovery program that targets the enzyme Fatty Acid Synthase or FASN.
Subscribe to our email newsletter
High levels of FASN are present in most cancer types and are associated with diminished patient survival. Reduction of FASN activity has been reported to lead to cancer cell death and decreased tumor size in many different cancer models. Sareum has used its expertise in small molecule drug discovery to identify novel chemical compounds that inhibit the activity of FASN and show efficacy in cancer cell survival models. The company aims to develop these compounds into potential therapies for a wide range of cancers.
The company also filed patent applications for novel small molecule compounds that have been discovered to be effective against an important cancer drug discovery target.
Tim Mitchell, Sareum’s CEO, said: “This program represent a significant development in Sareum’s internal drug candidate portfolio with key assets identified against important cancer drug discovery targets. The development and ultimate commercialization of these programs is a key value driver for the company.”